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Abstract: The recent emergence and re-emergence of viral infections transmitted by vectors, such as
the Zika virus (ZIKV) and Dengue virus (DENV), is a cause for international concern. These highly
pathogenic arboviruses represent a serious health burden in tropical and subtropical areas of the world.
Despite the high morbidity and mortality associated with these viral infections, antiviral therapies
are missing. Medicinal plants have been widely used to treat various infectious diseases since
millenaries. Several compounds extracted from plants exhibit potent effects against viruses in vitro,
calling for further investigations regarding their efficacy as antiviral drugs. Here, we demonstrate
that an extract from Psiloxylon mauritianum, an endemic medicinal plant from Reunion Island, inhibits
the infection of ZIKV in vitro without exhibiting cytotoxic effects. The extract was active against
different ZIKV African and Asian strains, including an epidemic one. Time-of-drug-addition assays
revealed that the P. mauritianum extract interfered with the attachment of the viral particles to the
host cells. Importantly, the P. mauritianum extract was also able to prevent the infection of human
cells by four dengue virus serotypes. Due to its potency and ability to target ZIKV and DENV
particles, P. mauritianum may be of value for identifying and characterizing antiviral compounds to
fight medically-important flaviviruses.
Keywords: Zika virus; Dengue virus; antiviral activity; natural compounds; nutraceuticals;
Psiloxylon mauritianum
1. Introduction
The Zika virus (ZIKV) and Dengue virus (DENV) are mosquito-borne enveloped viruses belonging
to the Flavivirus genus and constitute a worrisome threat to global human health [1,2]. The genome of
flaviviruses consists of a positive-sense single stranded RNA of approximately 11 kb [3]. After the viral
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processing of the polyprotein, ten viral proteins are produced: three structural proteins (C, M and E)
and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) [4]. The E protein
mediates the attachment of the viral particles to the host cell membrane [5]. This step is necessary for
the establishment of the infection [6,7].
Dengue fever, caused by 4 viral serotypes (DENV 1–4), is the most prevalent mosquito-borne viral
infection in tropical and subtropical countries, including the southwest of the Indian Ocean region [2].
An epidemic of DENV-2 is currently taking place in the French overseas region Reunion Island. ZIKV
causes important outbreaks in the South Pacific, Americas and South-East Asia. The recent ZIKV
epidemics in French Polynesia and South America were associated with severe fetal brain injury and
neurological defects in adults such as the Guillain-Barré syndrome [8–11]. ZIKV infection is now
identified as a sexually transmitted illness as well [12,13]. Phylogenetic studies allowed the division of
ZIKV into African and Asian lineages [14]. Since 2007, the leading cause of major epidemics is the
ZIKV Asian genotype [15].
Medicinal plants, which have been used as a treatment or prevention against several human
infectious diseases for millenaries, remain a remarkable potential source of antiviral compounds
against flaviviruses [16,17]. The Reunion Island, which belongs to the Mascarene Archipelago,
is classified as a biodiversity hotspot due to its exceptional flora and endemic plants. These could
provide active phytochemicals against viral infections [18–20]. Phytochemicals, including alkaloids,
coumarins, flavonoids, terpenoids, polyphenolics and saponins, have already been described for their
antiviral activity against numerous enveloped RNA viruses including flaviviruses [17,21–23]. Indeed,
the polyphenols epigallocatechin gallate (EGCG) from green tea, delphinidin, and curcumin, have
been found to inhibit ZIKV and DENV infection [24–27]. We recently reported that a polyphenol-rich
extract from Aphloia theiformis, an indigenous medicinal plant from Reunion Island, prevents ZIKV and
DENV infection through an inhibition of the virus entry steps [28]. Psiloxylon mauritianum, an endemic
medicinal plant recently listed in the French pharmacopoeia, has been extensively used in folk medicine
among the local people of the Mascarene Islands in the Indian Ocean [29,30]. Given the high content of
polyphenols in a P. mauritianum extract, we decided to evaluate its ability to inhibit ZIKV and DENV
infection. In the present study, we showed that P. mauritianum severely restricts the binding of virus
particles to the host-cells.
2. Results
2.1. Psiloxylon Mauritianum Extract Did Not Induce Genotoxicity in Human Cells
Prior to evaluating the potential antiviral activity of the Psiloxylon mauritianum extract,
we determined whether it exhibited cytotoxic and genotoxic effects on different mammalian cell lines,
using MTT and COMET assays, respectively. The cells were treated with different concentrations of the
P. mauritianum extract ranging from 4 to 2000 µg mL−1. The results showed a concentration-dependent
toxicity with a cell viability beginning to decrease starting at concentrations higher than 250 µg mL−1.
The cytotoxic concentration that inhibited 50% of the cell viability (CC50) was 1044 ± 106.2 µg mL−1
and 657 ± 15.7 µg mL−1, for Vero and A549 cells, respectively (Figure 1A). We also determined
the CC50 on human primary keratinocytes (HKPM) and fibroblast (FMa) cells. Figure 1B shows
dose-response curves, with a CC50 for HKPM and FMa of 353 ± 84.4 µg mL−1 and 820 ± 26.5 µg mL−1,
respectively (Figure 1B). We next determined the maximal noncytotoxic concentration (MNTC) on
different mammalian cell lines, using a nonlinear regression curve. The concentration of 100 µg mL−1 of
the P. mauritianum extract, that maintained 90% of Vero and A549 cell viability (Figure 1A), was chosen
to test the potential antiviral activity of the P. mauritianum extract on Vero cells.
To further characterize the toxicity of the P. mauritianum extract, we analyzed human cell DNA
damage by a COMET assay. A549 cells were treated with a maximal noncytotoxic concentration
(MNTC) of P. mauritianum (100 µg mL−1) for 24 h, and their DNA degradation was then analyzed
with a COMET assay. H2O2, which is known to induce DNA degradation [31], was used as a positive
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control. No comet formation and no DNA degradation were observed in the cells treated with the
P. mauritianum extract (Figure 1C,D). However, the COMETs were clearly visible when the cells were
treated with the positive control H2O2 (Figure 1C,D). We obtained the same results using a cytotoxic
concentration (500 µg mL−1) of the P. mauritianum extract on A549 cells (Figure S1).
These results suggest that the P. mauritianum extract did not induce human cell DNA degradation,
even at a cytotoxic concentration.
Figure 1. The cytotoxicity and genotoxicity of the P. mauritianum extract on mammalian cells. (A) Vero
and A549 cells were incubated with different concentrations of the P. mauritianum extract for 24 h.
The cell viability was determined using the metabolic activity by an MTT assay. (B) Human primary
keratinocytes (HKPM) and fibroblasts (FMa) were treated with an increased concentration of the
P. mauritianum extract for 24 h, and their viability was evaluated by an MTT assay. (A,B) The results are
the means ± SD of three independent experiments and are expressed as the relative value compared
to untreated cells. (C) Human cells (A549, HKPM and FMa) were treated 24 h with 100 µg mL−1 of
the P. mauritianum extract. The cells were treated 10 min with H2O2 (50 µM) as a positive control.
The genotoxicity was determined by observation of DNA degradation using a COMET assay visualized
by Gel Red. The images are representative of three independent experiments. Scale bars are 50 µm.
(D) The quantification of the COMET signal from the experiments represented in the images by using
a COMET assay IV software. The results are means ± SD of three independent experiments and are
expressed as the percentage of the tail intensity. A one-way ANOVA and Dunnett’s test for multiple
comparisons were used for the statistical analysis (*** p < 0.001).
2.2. P. mauritianum Extract Inhibits ZIKV Attachment to Mammalian Cell Surface
To assess the antiviral activity and determine which steps of viral replication were affected by
the P. mauritianum extract, time-of-drug-addition assays were performed in Vero cells (Figure 2A),
as previously described [28], using a chimeric molecular clone of the ZIKV strain MR766 expressing a
GFP reporter gene (ZIKVGFP) [32]. This virus allows the monitoring of viral replication by assessing
GFP fluorescence by flow cytometry. The ‘pre-adsorption’ experimental condition provides an insight
into the ability of the plant extract to prevent a ZIKV infection by potentially interacting with ZIKV
receptors or inducing an immuno-stimulating effect. The ‘adsorption’ experimental condition evaluates
the capacity of the plant extract to interfere with the internalization process of the viral particles into
the host-cell. The ‘post-adsorption’ experimental condition determines whether the extract is efficient
at inhibiting the intracellular replication and polyprotein processing/synthesis of ZIKV [4]. When
100 µg mL−1 of P. mauritianum extract was added throughout the experiment and concomitantly to the
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virus for 2 h (adsorption), the fluorescence intensity representing the viral replication was detected
only in 2% of cells (Figure 2B). By contrast, no effect was observed when the P. mauritianum extract was
added at pre-adsorption or 2 h post-adsorption (Figure 2B). These results suggest that the antiviral
activity of the P. mauritianum extract was not mediated by the inhibition of the viral protein production
but rather by the inhibition of early steps of the viral replication, possibly viral entry mechanisms.
Figure 2. P. mauritianum extract inhibits ZIKV attachment to the cell surface. (A) Schematic
representation of time-of-drug-addition assays used to characterize the antiviral activity of the
P. mauritianum extract (100 µg mL−1). Green arrow indicates the presence of the plant extract. (B) Flow
cytometric analysis of GFP expression in Vero cells infected with ZIKVGFP during 24 h at MOI of
1 under the different experimental conditions shown in (A). The results are means ± SD of three
independent experiments and are expressed as the relative value compared to untreated infected cells.
(C) Virus binding assays: Vero cells were infected with ZIKV-MR766 at MOI of 1 for 1 h at 4 ◦C with or
without 100 µg mL−1 of the P. mauritianum extract. EGCG (100 µM) were used as a positive control.
The number of virus particles bound to the cell surface was measured by RT-qPCR. The values represent
the mean ± SD of three independent experiments. (D) Viral inactivation assays: Vero cells were infected
with ZIKVGFP pre-incubated during 1 h at 37 ◦C with four different concentration of P. mauritianum
extract. A flow cytometric analysis of GFP fluorescence was performed 24 hp.i. The results shown are
means ± SD of three independent experiments and are expressed as the relative value compared to
untreated infected cells. Statistical analyses were performed using a one-way ANOVA and Dunnett’s
test for multiple comparisons (*** p < 0.001; **** p < 0.0001; n.s = not significant).
The early steps of the viral infection include binding to the cell surface and internalization via
endocytosis. To determine which of these steps are targeted by the P. mauritianum extract, viruses
generated with the ZIKV-MR766 strain molecular clone were incubated on Vero cells for 1 h at 4 ◦C,
to allow the attachment to the cell surface and prevent viral internalization, in the presence or absence
of the P. mauritianum extract (100 µg mL−1). The amount of attached ZIKV particles was determined by
RT-qPCR. EGCG, which is known to inhibit the ZIKV attachment [27,28,33], was used as a positive
control. Our data show that 10 times less viral particles were attached to the surface of the cell
membrane in the presence of the P. mauritianum extract, as compared to the untreated control cells
(Figure 2C). Thus, the treatment with the P. mauritianum extract significantly affects ZIKV binding to
the cell surface (Figure 2C).
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We also performed a viral inactivation assay to determine if the P. mauritianum extract neutralizes
ZIKV infectivity. Briefly, ZIKVGFP particles were incubated for 1 h at 37 ◦C with different concentrations
of plant extract, prior to infection [28]. At 24 h post-infection, a significant decrease of GFP-positive
cells (up to 80%) was observed in cells treated with 100 µg mL−1 of the plant extract, as compared to
untreated ones (Figure 2D). Using a nonlinear regression curve, the concentration of P. mauritianum that
inhibits 50% of ZIKV infection (IC50) was estimated at 19.5 ± 4.8 µg mL−1. Based on the cytotoxicity and
the antiviral activity, the selectivity index (SI = CC50/IC50) was then calculated. The SI of P. mauritianum
was 53.5. Together, these results suggest that the antiviral activity of the P. mauritianum extract is
mediated by an interaction between the extract and ZIKV particles.
2.3. P. mauritianum Extract Inhibits Infection of African and Asian Lineages of ZIKV
To further validate the potential anti-ZIKV activities of the P. mauritianum extract, the African
lineage strain ZIKV-MR766 was incubated with the P. mauritianum extract for 1 h at 37 ◦C prior to the
Vero cells infection through the viral inactivation assay. Several methods were used to assess the viral
infection: the viral replication was evaluated by the presence of single-stranded viral RNA (ssRNA) using
fluorescence in situ hybridisation (FISH)-based assays, the viral protein production was quantified by
immunofluorescence assays and the viral production was measured by plaque forming assays.
The production of ssRNA was first measured by FISH coupled to confocal microscopy 24 h
post-infection (hp.i). The cells treated with EGCG, which is known to inhibit ZIKV entry [26,28,33],
were used as positive controls. The FISH probe produced no signal in the non-infected control cells
and a bright signal in the cytoplasm of the infected cells (Figure 3A), validating its specificity. To better
visualize the edge of the cells and the localisation of ssRNA, a fluorescence dye binding to cellular
membranes was included in the analysis. The incubation of ZIKV-MR766 with the P. mauritianum
extract resulted in a significant reduction of the number of ssRNA molecules per field, as compared to
mock-treated infected cells (Figure 3B).
Figure 3. P. mauritianum extract inhibits the production of ZIKV ssRNA. ZIKV-MR766 particles were
incubated with the P. mauritianum extract for 1 h at 37 ◦C. The EGCG treatment (100 µM) was used
as positive control. Vero cells were left uninfected or were infected at an MOI of 1 for 24 h. (A) Cells
were processed for FISH using a probe specific for viral RNA (red) and then stained with NucBlue to
visualize the nuclei (blue). Cell membranes were stained with AF488-conjugated wheat germ agglutinin.
Images are representative of three independent experiments. Scale bars are 20 µm. (B) Quantification
of ZIKV ssRNA spots counted per field (fields contained on average 300 cells) from the experiments
represented in the images. Data are means ± SD of three independent experiments. Statistical analyses
were performed using a one-way ANOVA and Dunnett’s test for multiple comparisons (**** p < 0.0001).
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In parallel, the viral protein production was evaluated 24 hp.i by immunofluorescence assays,
using an antibody that recognizes the viral protein E. The EGCG treatment was used as a positive control.
To determine whether the P. mauritianum extract exhibited an antiviral activity against another viral
strain, the contemporary Asian lineage ZIKV-PF13, which was responsible for the epidemic in 2013 in
French Polynesia, was included in the analysis [34]. The production of the viral protein E of both strains
was affected by 100 µg mL−1 of the P. mauritianum extract (Figure 4A). The percentage of ZIKV-infected
cells was reduced to 16% and 9% in the presence of P. mauritianum, upon infection with ZIKV-MR766
and ZIKV-PF13, respectively (Figure 4B,C). By contrast, up to 60% of the non-treated cells were infected
(Figure 4B,C). The extract was as potent as EGCG in inhibiting the ZIKV infection (Figure 4B,C). In this
assay, ZIKV-PF13 was as sensitive as the African lineage to the P. mauritianum treatment.
Figure 4. Antiviral activity of the P. mauritianum extract against the African and Asian ZIKV lineages.
ZIKV-MR766 or ZIKV-PF13 were incubated with the P. mauritianum extract for 1 h at 37 ◦C. EGCG
(100 µM) was used as a positive control. The Vero cells were infected at a MOI of 1 for 24 h. (A) The
cells were processed for an immunofluorescence assay. The ZIKV E protein (red) and nuclei (blue)
were visualized by fluorescence microscopy. The images are representatives of three independent
experiments. Scale bars are 50 µm. The quantification of the number of (B) ZIKV-MR766 and (C)
ZIKV-PF13 infected Vero cells from the experiments are represented in the images. The results shown
are the means ± SD of three independent experiments. Statistical analyses were performed using a
one-way ANOVA and Dunnett’s test for multiple comparisons (**** p < 0.0001).
Finally, plaque forming assays confirmed that both strains were sensitive to the P. mauritianum
extract (Figure 5A,B). At the maximal noncytotoxic concentration of 100 µg mL−1, P. mauritianum
decreased up to 2-log the production of infectious viral particles (Figure 5A,B). ZIKV-MR766 appeared
to be slightly more sensitive than ZIKV-PF13 to the P. mauritianum extract.
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Figure 5. The P. mauritianum extract reduces the viral progeny production of the African and Asian
ZIKV lineages. (A) ZIKV-MR766 or (B) ZIKV-PF13 were incubated with different concentrations of the
P. mauritianum extract for 1 h at 37 ◦C. The Vero cells were infected at a MOI of 1 for 24 h. The release of
infectious viral particles was measured by plaque forming assays. The results shown are the means± SD
of three independent experiments. Statistical analyses were performed using a one-way ANOVA and
Dunnett’s test for multiple comparisons (** p < 0.01; *** p < 0.001).
2.4. P. mauritianum Extract Exerts Antiviral Activity against Four DENV Serotypes
We next wondered if the P. mauritianum extract exerts an antiviral activity against DENV, another
medically-relevant flavivirus. The anti-DENV activity of the P. mauritianum extract was evaluated using
four different serotypes (clinical isolates for DENV1-3 and a DENV-4 lab-adapted strain). The treatment
with IFN-α 2A, which is known to block DENV replication [35], was used as a positive control.
The P. mauritianum extract (100 µg mL−1) was pre-incubated with the four different serotypes of DENV
for 1 h at 37 ◦C prior to infection. The human hepatoma cell lines Huh7.5, which are extensively used in
Flaviviridae research and relevant for DENV infection [36,37], were used to perform these experiments.
The cytotoxicity effect of the P. mauritianum extract on Huh7.5 cells was first evaluated using MTT
assays. The concentration of 100 µg mL−1 of P. mauritianum did not affect the cell viability after 48 h of
treatment (Figure S2).
The number of E-positive cells were quantified at 48 hp.i using antibodies against the E protein
and the Operetta High-Content Imaging System (PerkinElmer). The P. mauritianum extract significantly
decreased the number of E-positive cells (Figure 6A). DENV-3 and -4 appeared more sensitive to the
P. mauritianum action than DENV-1 and -2 (Figure 6A). The production of infectious viral particles was
then quantified using foci forming immunodetection assays to relate the reduction of the number of
E-positive cells to the DENV infectivity. A decrease of up to 2 log of the DENV infectivity was observed
upon DENV-3 and -4 infections when the virions were treated with 100 µg mL−1 of the P. mauritianum
extract (Figure 6B). These results show that the P. mauritianum extract exhibits potent antiviral activity
against the four DENV serotypes.
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Figure 6. The P. mauritianum extract inhibits the infection of four DENV clinical isolates representative
of the four serotypes. Four DENV serotypes (DENV-1, 2, 3 and 4) were pre-incubated with the
P. mauritianum extract for 1 h at 37 ◦C. (A) Huh7.5 cells were infected for 48 h with DENV at the different
MOI 0.2, 2, 0.5 and 2 for DENV 1–4, respectively. Recombinant IFN-α 2A (200 IU mL−1) was added
2 h post-infection and used as a positive control. The percentage of E positive cells was evaluated
using the Operetta High-Content Imaging System (PerkinElmer). The results are the means ± SD of
three independent experiments. (B) The residual infectious particles were titrated in C6/36 cells using
a foci-forming immunodetection assay. The data represent the means ± SD from three independent
experiments. A one-way ANOVA and Dunnett’s test for multiple comparisons were used for the
statistical analysis (** p < 0.01; *** p < 0.001; **** p < 0.0001).
3. Discussion
Despite the recent ZIKV emergence worldwide and its subsequent classification as a major public
health problem by the World Health Organization in 2016 [1], there are still no vaccine or licensed
antivirals. Thus, the use of medicinal plants as a simple and economical means of treating the viral
infection merits investigations. In this study, we evaluated the antiviral activity of Psiloxylon mauritianum
extract against ZIKV and DENV. Our data demonstrate that non-toxic concentrations of P. mauritianum
(100 µg mL−1) significantly reduced the ZIKV infection in Vero cells, regardless of the ZIKV strains
tested (historic and epidemic strains). We also demonstrated that P. mauritianum extract prevents the
infection of human cells by four DENV serotypes. We showed that P. mauritianum extract acts on
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early steps of the viral replication cycle, in a similar way than EGCG, a green tea polyphenol, which
is known to inhibit viral entry into the host cells [27,28,33]. Our attachment and viral inactivation
assays show that P. mauritianum extract inhibits the viral attachment to the cell surface, probably via a
direct interaction with the outer membrane of ZIKV particles. This type of interaction was previously
described between EGCG and ZIKV or DENV particles [26–28]. We propose that the active compounds
of P. mauritianum extract act through a similar mechanism, probably via binding to the surface of
the virions.
P. mauritianum is an endemic medicinal plant of the Mascarene Islands, more specifically of
the Reunion and Mauritius Islands. The folk use of this plant has been described for the treatment
and management of amenorrhea, dysentery and common infectious diseases [29,38,39]. The high
amount of polyphenols of this endemic medicinal plant provides a significant antioxidant activity [39].
Our phytochemical analysis of P. mauritianum extract, performed with an ultra-high-performance liquid
chromatography-diode array detector coupled to mass spectrometry (UHPLC-DAD-MS), confirmed the
phenolic-richness composition of this plant, mainly a glycosylated derivate of gallic acid, quercetin and
kaempferol (Figure S3 and Table S1). Indeed, numerous polyphenol compounds have been described
for their anti-flavivirus activities, such as EGCG, which is also efficient against a broad spectrum of
enveloped RNA and DNA viruses [27,33,40–44], delphinidin [27], naringenin [35], isoquercitrin [23] and
curcumin [25]. Likewise, we have recently shown that another polyphenol-rich extract from Reunion
Island medicinal plant Aphloia theiformis inhibits ZIKV and DENV infection [28]. Thus, it would be of
great interest to identify the phytochemicals responsible for P. mauritianum and A. theiformis antiviral
activities or whether there is a synergetic effect of several compounds leading to antiviral activity.
Importantly, in addition to this antiviral activity, we demonstrated that P. mauritianum extract did
not exert a genotoxic effect on several mammalian cells, including human primary cells relevant for
arboviral infection. Our COMET assay showed that the plant extract did not cause any deleterious
effect on the cell DNA. Previous studies assessing the genotoxicity of medicinal plants showed great
variability in their genotoxic potential, depending on the plants and types of extracts tested [45–48].
We demonstrated that P. mauritianum did not exert a high cytotoxicity regardless of the cell lines tested.
These non-deleterious effects further indicate that P. mauritianum extract is a potential candidate for the
development of new antiviral drugs to fight ZIKV and DENV infections.
In conclusion, our data demonstrated that the extract from Psiloxylon mauritianum, an endemic
medicinal plant from the Reunion and Mauritius Islands, exhibits an antiviral activity against historical
and contemporary strains of ZIKV, as well as against four clinical isolates of DENV. Moreover, this plant
extract does not exert a deleterious effect on mammalian cells, revealing that it could be an important
source for antiviral drugs to treat Zika and Dengue fever in patients.
4. Materials and Methods
4.1. Cells, Viruses and Reagents
Vero cells (ATCC, CCL-81) and human-derived Huh7.5 hepatoma cells (ATCC, PTA-8561TM;
Manassas, VA, USA) were cultured in an Eagle minimum essential medium (MEM) supplemented
with a 5% heat-inactivated Fetal Bovine Serum (FBS), 2 mmol L−1 L-Glutamine, 1 mmol L−1 sodium
pyruvate, 100 U mL−1 of penicillin, 0.1 mg mL−1 of streptomycin and 0.5 µg mL−1 of fungizone
(Amphotericin B) (PAN Biotech, Aidenbach, Germany) under a 5% CO2 atmosphere at 37 ◦C. A549 cells
(ATCC, CCL-185) were cultured in DMEM glutamax supplemented with 10% of FBS, 100 U mL−1 of
penicillin, 0.1 mg mL−1 of streptomycin and 1% of non-essential amino acid (NEAA). Primary human
keratinocytes plasty mammary (HKPM) and fibroblast (FMa) cultures were established by outgrowth
from biopsies obtained immediately after breast plastic surgery from healthy donors, with their
informed consent (Centre Hospitalier de Grenoble, Grenoble, France). Keratinocytes were cultured in
Keratinocyte Serum-Free medium (KSFM) supplemented with 25 µg mL−1 Bovine Pituitary Extract
(BPE), 1.5 ng mL−1 Epidermal Growth Factors (EGF) and 75 µg mL−1 primocin. C6/36 Aedes albopictus
Int. J. Mol. Sci. 2019, 20, 1860 10 of 16
cells (ATCC CRL-1660, Manassas, VA, USA) were maintained at 27 ◦C in Leibovitz’s L-15 medium
supplemented with 10% heat-inactivated FBS, 1% P/S, 1% MEM Non-Essential Amino Acids solution
(Gibco/Invitrogen, Carlsbad, CA, USA) and 2% Tryptose Phosphate Browth (Gibco). The clinical isolate
PF-25013-18 of ZIKV has been previously described [34,49]. ZIKVMC-MR766NIID and the GFP-expressing
strain of ZIKVMC-MR766NIID (ZIKVGFP) are molecular clones of the ancestral strain MR766 of ZIKV [32].
DENV-1/FGA/89 was isolated in 1989 from a South American patient suffering from DF (GenBank:
AF226687). DENV-2/ICC-265 was isolated from a DF patient in Brazil in 2009. DENV3/5532 was
isolated in 2007 from a fatal case of dengue with visceral manifestations in a patient in Paraguay
(GenBank: HG235027). DENV-4/TVP360 is a laboratory strain that was kindly provided by Dr. Ricardo
Galler (Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; GenBank: KU513442). DENV stocks were
grown in C6/36 cells and titrated by a foci-forming immunodetection assay. Vero cells were infected
with a MOI of 1. ZIKV strains were amplified on Vero cells. The anti-pan flavivirus E monoclonal
antibody 4G2-Alexa Fluor 594 was purchased from RD Biotech.
4.2. Extraction of Plant Material
Fresh aerial parts of Psiloxylon mauritianum were collected in Reunion Island in 2016–2017.
The voucher specimens (JF 1004) were deposited in the herbarium of the University of Reunion Island.
A solvent-free microwave extraction was applied on P. mauritianum fresh aerial parts. After heating
500 g of plant material for 20 min at 800 W using an IDCO E200 extractor (IDCO SAS, Marseille, France),
the extract was recovered by gravity. The aqueous extract was lyophilized using cryotec 20K (Cryotec,
Saint-Gély-du-Fesc, France). The powder was then solubilized on sterile water and stored at −80 ◦C
until used.
4.3. Cytotoxicity Assays
Two-fold dilutions of plant extract ranging from 4 to 2000 µg mL−1 were used to treat Vero,
A549, HKPM and FMa cells at a density of 1×104 cells per cultured well, in 96-well culture plates.
The cells were rinsed with PBS 1×, and 120 µL of the culture medium mixed with 5 mg mL−1 MTT
(3-[4-dimethylthiazol-2-yl]-2,5-diphenyltetrahzolium bromide) solution was added, after an incubation
period of 24 h at 37 ◦C. Following an incubation of 2 h, the MTT medium was removed and the
formazan crystals was solubilized with 100 µL of Dimethyl sulfoxide (DMSO). The absorbance was
measured at 570 nm with a background subtraction at 690 nm. The CC50 was determined using a
nonlinear regression on the Graphpad prism software (version 7.0; La Jola, CA, USA).
4.4. COMET Assays
A549, HKPM and FMa cells were seeded in 12-well plates one day before treatment. The cells
were treated with different concentrations of plant extract during 24 h, then trypsinized, and kept in a
freezing buffer until storage at −80 ◦C. Cell suspensions (100 µL) were mixed with 900 µL of 0.6% low
melt agarose to obtained a density of 2×106 cell mL−1. On agarose pre-coated slides, 100 µL of this
suspension was put down and kept on ice for 10 min. A H2O2 (50 µM) treatment during 10 min was
used as positive control. The slides were then brought in a lysis buffer for 1 h in the dark (pH 10, 2.5 M
NaCl; 10 mM TRIS; 0.1 M EDTA; 1% Triton X-100; 10% DMSO). Following this, the slides were rinsed
three times using a diluted Tris-HCl buffer (1.2 mM TRIS pH adjusted to pH 7.4 with concentrated
HCl). Electrophoresis were performed on the slides for 30 min at 21 V in a cold denaturation buffer
(0.3 M NaOH; 1 mM EDTA). After washing, the slides were stained with 50 µL of Gel Red (1:10000).
The slides were observed using Zeiss Axioskop 2.0 with an Alled vision technologies camera (Stadtroda,
Germany). The pictures were acquired and analyzed using the COMET assay IV software (Instem,
Stone, UK).
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4.5. Immunofluorescence and Flow Cytometry Assays
For the immunofluorescence assay, the cells were fixed (PFA, 3.7%) and permeabilized for 5 min
(PBS 1× 0.15% Triton X-100) 24 hp.i. The cells were stained 1 h at room temperature in the dark for
ZIKV using 4G2-Alexa Fluor 594 (1:1000 in PBS-BSA 2%). The DAPI staining was used to delineate
the cells’ nuclei. Coverslips were mounted in Vectashield and the fluorescence was observed using a
Nikon Eclipse E2000-U microscope. The Hamamatsu ORCA-ER camera and NIS-Element AR (Nikon)
imaging software were used to capture images. For the flow cytometry assay, cells were harvested,
followed by a fixation with paraformaldehyde 3.7% for 10 min. Then they were submitted to a flow
cytometry analysis using CytoFLEX (Beckman Coulter, Brea, CA, USA). The results were analyzed
using the Cytexpert software (Brea, CA, USA).
4.6. Virus Binding Assays
Virus binding assays were performed as previously described [23,28]. Briefly, Vero cells were
seeded in 6-well plates at a density of 2 × 105 cell per well. Pre-chilled cells were incubated with
ZIKV-MR766 at MOI 1 with or without P. mauritianum extract for 1 h at 4 ◦C. Then, the virus input was
removed and the cells were washed with cold MEM supplemented with 2% FBS. The samples were
then submitted to RT-qPCR.
4.7. Virus Inactivation Assays
Virus inactivation assays were performed as previously described [23,28]. Briefly, ZIKV-MR766 or
ZIKV-PF13 (2 × 105 PFU) were mixed with P. mauritianum extract (100 µg mL−1) and then incubated
for 1 h at 37 ◦C. Simultaneously, the same amount of virus was incubated with the medium without
the plant extract as a control. The mixture (plant extract-virus) was then diluted 50-fold (final virus
concentration, 1 PFU/cell) with MEM containing 2% FCS to yield a subtherapeutic concentration of
plant extract, and the mixture was subsequently added to a Vero cell monolayer seeded in 6-well
plates. As a comparison, ZIKV was mixed with P. mauritanum, diluted immediately to 50-fold without
an incubation period and added to the Vero cells for infection. The 50-fold dilution served to titrate
the plant extract below its effective dose and prevent meaningful interactions with the host cell
surface. The inocula were discarded after 2 h of adsorption at 37 ◦C, the cells were washed with PBS
twice and the incubation was maintained for 24 h at 37 ◦C before being subjected to cytometry or
immunofluorescence assays as described above.
4.8. RT-qPCR
The total RNA, including genomic viral RNA, was extracted from cells with an RNeasy kit (Qiagen,
Hilden, Germany) and reverse transcribed using an E reverse primer (5′-TTCACCTTGTGTTGGGC-3′)
and M-MLV reverse transcriptase (Life Technologies, Villebon-sur-Yvette, France) at 42 ◦C for 50 min.
A quantitative PCR was performed on a CFX96 Real-Time PCR Detection System (Applied Biosystems,
Life Technologies, Villebon-sur-Yvette, France). Briefly, cDNA was amplified using 0.2 µM of each
primer and GoTaq Master Mix (Promega, Charbonnières-les-bains, France). For each single-well
amplification reaction, a threshold cycle (Ct) was calculated using the CFX96 program (Bio-Rad) in
the exponential phase of amplification. A synthetic gene coding for the nucleotides 954 to 1306 of the
MR766 strain (GenBank: LC002520) cloned in the pUC57 plasmid was used as template to generate a
standard curve, which then served to make an absolute quantitation of the bound viruses.
4.9. Plaque Forming Assays
Plaque forming unit assays were used to quantify the release of infectious viral particles [23,28].
Vero cells were seeded the previous day in 48-well culture plates at a density of 3×104 cells per well.
Cells were infected by 0.1 mL of ten-fold dilutions of supernatant. Following an incubation of 2 h
at 37 ◦C, 0.2 mL of the culture medium supplemented with 5% fetal bovine serum (FBS) and 0.8%
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carboxymethylcellulose sodium salt (Sigma-Aldrich, Saint-Quentin-Fallavier, France)) were added,
and the incubation was extended for 4 days at 37 ◦C. Cells were fixed (PFA, 3.7%) and stained with
0.5% crystal violet (Sigma-Aldrich) diluted in 20% ethanol, after the media had been removed. Plaques
were counted and expressed as plaque-forming unit per mL (PFU mL−1).
4.10. Foci-Forming Immunodetection Assay
C6/36 cells were seeded at a density of 1×105 in 24 well plates and incubated overnight at 37 ◦C
to perform a foci-forming immunodetection assay. Ten-fold serial dilutions of the supernatant were
prepared in duplicate in the culture medium and 0.4 mL of each dilution was added to the cells for 1 h
30 min. Then, the inoculum was removed and a CMC media (L-15 supplemented with 10% FBS, 0.52%
tryptose, 50 mg mL−1 gentamicin, 1.6% carboxymethylcellulose) was added. After seven days of being
incubated, immunostaining was performed using the mouse monoclonal antibody 4G2 followed by
goat-antimouse immunoglobulin conjugated to alkaline phosphatase (Promega, Madison, WI, USA).
A solution of NBT (nitroblue tetrazolium chloride) and BCIP (5-bromo-4-chloro-39-indolyphosphate
p-toluidine salt) (Promega, Madison, WI, USA) was used as a substrate to detect antibodies. The foci
were counted and expressed as FFU mL−1.
4.11. Quantification of the Number of ZIKV-ssRNA Molecules by Fluorescence In Situ Hybridization (FISH)
and Confocal Analysis
The ZIKV strains were pre-incubated for 1 h at 37 ◦C with plant extracts in DMEM before
infection. P. mauritianum extract was used at a final concentration of 100 µg mL−1 and EGCG at a final
concentration of 100 µM. Vero cells were then infected at MOI of 1 for 24 h with viruses treated or
not with the drugs. After fixation with 4% PFA for 30 min at RT, the cells were stained with wheat
germ agglutinin (WGA) AF-488 conjugate (Thermo Fisher Scientific, Waltham, MA, USA) in PBS-BSA
0.5% overnight at 4 ◦C. After immunostaining, ZIKV plus strand RNA was detected using Alexa-Fluor
546-conjugated probe sets recognizing the regions between nt 2 and 1144 of the ZIKV genome (Thermo
Fisher Scientific). The samples were processed following the manufacturer ‘ViewRNA ISH Cells
Assays’ protocol. The nuclei were stained with NucBlue (Thermo Fisher Scientific) for 15 min at RT.
The images were acquired with a Zeiss LSM 700 laser scanning confocal microscope equipped with an
X63 objective (Zeiss, Oberkochen, Germany). The images were processed with Zen2 (blue edition)
software and analyzed with the ICY software (icy.bioimageanalysis.org) using the Spot Detector plugin.
The number of individual RNAs per field was analyzed by assembling 3 × 3 images. A detection filter
based on a size of 3 pixels in diameter (with a minimum of 2 pixels and a maximum of 5) was set up.
Based on this size parameter, all the fluorescent signals, including ‘aggregated’ RNAs, were analyzed
by the software and decomposed into individual RNA.
4.12. Data Analysis
Comparison between different concentrations was done by a one-way ANOVA test. All values
were expressed as mean ± SD of at least three independent experiments. All statistical tests were done
using the software Graph-Pad Prism (version 7.0; La Jola, CA, USA). Values of p < 0.05 were considered
statistically significant for a Dunnett’s multiple comparisons test. Degrees of significance are indicated
on the figure as follow: * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001, n.s = not significant.
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Author Contributions: Conceptualization, P.G., C.E.K.; methodology, E.C., J.G.H., A.C.K., L.S., C.E.K.; formal
analysis, E.C., J.G.H., A.C.K., L.S., C.N.D.d.S., N.J., C.E.K.; investigation, E.C., J.G.H., A.C.K., L.S., W.R., P.D., P.G.,
C.N.D.d.S., N.J., C.E.K; writing—original draft preparation, E.C., C.E.K.; writing—review and editing, C.E.K., P.D.,
N.J.; supervision, C.E.K.; funding acquisition, P.D., C.E.K.
Funding: This work was supported by POE FEDER 2014-20 of the Conseil Régional de La Réunion (ZIKAlert
program, N◦ SYNERGIE: RE00001902), INSERM-Transfert (project: n◦R16029FS), CAPES-COFECUB Me889/17
ZIKANET project and Research Federation BioST, Université de La Réunion. E.C. is supported by a grant DIRED
Int. J. Mol. Sci. 2019, 20, 1860 13 of 16
from the Conseil Régional de La Réunion, France. J.-G.H. received funding from the ZIKAlert program. L.S. is
supported by the Pasteur Paris University (PPU) International PhD program through an ‘Institut Carnot Pasteur
Maladies Infectieuses’ grant.
Acknowledgments: We are grateful to Claude Marodon (Aplamedom) for helpful discussion on
ethnopharmacological uses of plants. We thank Marie Watson and Laurent Janci (CAHEB and Extraits De
Bourbon) for contribution in plant extractions. We are grateful to David Beal (CIBEST, Grenoble) for helpful
contribution in genotoxicity assays.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
Abbreviations
A549 Human lung epithelial cell line
CMC Carboxymethyl cellulose
COMET Single Cell gel electrophoresis
DENV Dengue virus
DMSO Dimethyl sulfoxide
DNA Desoxyribonucleic Acid
EDTA Ethylenediaminetetraacetic acid
EGCG Epigallocatechin gallate
FACS Fluorescence-activated cell sorting
GFP Green fluorescent protein
HKPM Primary human keratinocytes plasty mammary
hp.i Hours post infection
Huh-7.5 Human hepatoma cell line
MOI Multiplicity of infection
MTT 3-[4–dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
PBS Phosphate-buffered saline
PFA Paraformaldehyde
PFU Plaque forming unit
RNA Ribonucleic Acid
TRIS Tris(hydroxymethyl)aminomethane
ZIKV Zika virus
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